首页 > 最新文献

Blood Research最新文献

英文 中文
Fecal microbiota transplantation for steroid-refractory gastrointestinal graft-versus-host disease. 粪便微生物群移植治疗类固醇难治性胃肠移植物抗宿主病。
IF 2.2 Q3 Medicine Pub Date : 2023-09-30 Epub Date: 2023-07-11 DOI: 10.5045/br.2023.2023069
Hyun Min Kim, Joonyeop Lee, Seokjin Kim, Jong Wook Lee, Hee-Je Kim, Young-Seok Cho
2 AML (MSD) TBI (1320 cGy), CpS 60 mg/kg (2 days) 2 ATG MTX CsA MMF Ruxolitinib +140 Unrelated 1 colonoscopy C.difficile: negative Comorbid infection: CMV viremia +33 bacteremia (VSE) No response, died from hepatic GVHD and sepsis on day +174 3 Relapsed MM (MUD) Fludarabine 30 mg/m (5 days) 3 ATG MTX MMF FK +44 Unrelated 4 colonoscopy C.difficile: negative Comorbid infection: CMV viremia +10 after 1 FMT: infectious colitis +14 after 4 FMT: CMV colitis Partial response after ruxolitinib add on
{"title":"Fecal microbiota transplantation for steroid-refractory gastrointestinal graft-versus-host disease.","authors":"Hyun Min Kim, Joonyeop Lee, Seokjin Kim, Jong Wook Lee, Hee-Je Kim, Young-Seok Cho","doi":"10.5045/br.2023.2023069","DOIUrl":"10.5045/br.2023.2023069","url":null,"abstract":"2 AML (MSD) TBI (1320 cGy), CpS 60 mg/kg (2 days) 2 ATG MTX CsA MMF Ruxolitinib +140 Unrelated 1 colonoscopy C.difficile: negative Comorbid infection: CMV viremia +33 bacteremia (VSE) No response, died from hepatic GVHD and sepsis on day +174 3 Relapsed MM (MUD) Fludarabine 30 mg/m (5 days) 3 ATG MTX MMF FK +44 Unrelated 4 colonoscopy C.difficile: negative Comorbid infection: CMV viremia +10 after 1 FMT: infectious colitis +14 after 4 FMT: CMV colitis Partial response after ruxolitinib add on","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/df/40/br-58-3-145.PMC10548292.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9823322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigating the prevalence of and predictive and risk factors for pulmonary embolism in patients with COVID-19 in Nemazee Teaching Hospital. 调查Nemazee教学医院新冠肺炎患者肺栓塞的患病率、预测因素和危险因素。
IF 2.2 Q3 Medicine Pub Date : 2023-09-30 Epub Date: 2023-07-11 DOI: 10.5045/br.2023.2023076
Mahnaz Yadollahi, Hessam Hosseinalipour, Muhammad Alinaqi, Mehrdad Karajizadeh, Mehrdad Jowkar, Kazem Jamali, Maryam Yadollahi, Pooria Fazeli

Background: Pulmonary thromboembolism (PTE) is a significant contributing factor to vascular diseases. This study aimed to determine the prevalence of pulmonary thromboembolism and its predisposing factors in patients with COVID-19.

Methods: This cross-sectional study included 284 patients with COVID-19 who were admitted to Nemazee Teaching Hospital (Shiraz, Iran) between June and August 2021. All patients were diagnosed with COVID-19 by a physician based on clinical symptoms or positive polymerase chain reaction (PCR) test results. The collected data included demographic data and laboratory findings. Data were analyzed using the SPSS software. P≤0.05 was considered statistically significant.

Results: There was a significant difference in the mean age between the PTE group and non-PTE group (P=0.037). Moreover, the PTE group had a significantly higher prevalence of hypertension (36.7% vs. 21.8%, P=0.019), myocardial infarction (4.5% vs. 0%, P=0.006), and stroke (23.9% vs. 4.9%, P=0.0001). Direct bilirubin (P=0.03) and albumin (P=0.04) levels significantly differed between the PTE and non-PTE groups. Notably, there was a significant difference in the partial thromboplastin time (P=0.04) between the PTE and non-PTE groups. A regression analysis indicated that age (OR, 1.02; 95% CI, 1.00‒1.004; P=0.005), blood pressure (OR, 2.07; 95% CI, 1.12‒3.85; P=0.02), heart attack (OR, 1.02; 95% CI, 1.28‒6.06; P=0.009), and albumin level (OR, 0.39; 95% CI, 0.16‒0.97; P=0.04) were all independent predictors of PTE development.

Conclusion: Regression analysis revealed that age, blood pressure, heart attack, and albumin levels were independent predictors of PTE.

背景:肺血栓栓塞症(PTE)是导致血管疾病的重要因素。本研究旨在确定新冠肺炎患者肺血栓栓塞的患病率及其诱发因素。方法:本横断面研究包括2021年6月至8月期间入住Nemazee教学医院(伊朗设拉子)的284名新冠肺炎患者。医生根据临床症状或阳性聚合酶链式反应(PCR)检测结果诊断所有患者为新冠肺炎。收集的数据包括人口统计数据和实验室发现。使用SPSS软件对数据进行分析。P≤0.05被认为具有统计学意义。结果:PTE组和非PTE组的平均年龄有显著差异(P=0.037)。此外,PTE组高血压(36.7%对21.8%,P=0.019)、心肌梗死(4.5%对0%,P=0.006)、,PTE组和非PTE组的直接胆红素(P=0.03)和白蛋白(P=0.04)水平存在显著差异。值得注意的是,PTE组和非PTE组的部分凝血活酶时间存在显著差异(P=0.04)。回归分析表明,年龄(OR,1.02;95%可信区间,1.00-1.004;P=0.005)、血压(OR,2.07;95%置信区间,1.12-3.85;P=0.02)、心脏病发作(OR,1020;95%置信度,1.28-6.06;P=0.009)和白蛋白水平(OR,0.39;95%CI,0.16-0.97;P=0.04)都是PTE发展的独立预测因素。结论:回归分析显示,年龄、血压、心脏病发作和白蛋白水平是PTE的独立预测因素。
{"title":"Investigating the prevalence of and predictive and risk factors for pulmonary embolism in patients with COVID-19 in Nemazee Teaching Hospital.","authors":"Mahnaz Yadollahi,&nbsp;Hessam Hosseinalipour,&nbsp;Muhammad Alinaqi,&nbsp;Mehrdad Karajizadeh,&nbsp;Mehrdad Jowkar,&nbsp;Kazem Jamali,&nbsp;Maryam Yadollahi,&nbsp;Pooria Fazeli","doi":"10.5045/br.2023.2023076","DOIUrl":"10.5045/br.2023.2023076","url":null,"abstract":"<p><strong>Background: </strong>Pulmonary thromboembolism (PTE) is a significant contributing factor to vascular diseases. This study aimed to determine the prevalence of pulmonary thromboembolism and its predisposing factors in patients with COVID-19.</p><p><strong>Methods: </strong>This cross-sectional study included 284 patients with COVID-19 who were admitted to Nemazee Teaching Hospital (Shiraz, Iran) between June and August 2021. All patients were diagnosed with COVID-19 by a physician based on clinical symptoms or positive polymerase chain reaction (PCR) test results. The collected data included demographic data and laboratory findings. Data were analyzed using the SPSS software. <i>P</i>≤0.05 was considered statistically significant.</p><p><strong>Results: </strong>There was a significant difference in the mean age between the PTE group and non-PTE group (<i>P</i>=0.037). Moreover, the PTE group had a significantly higher prevalence of hypertension (36.7% vs. 21.8%, <i>P</i>=0.019), myocardial infarction (4.5% vs. 0%, <i>P</i>=0.006), and stroke (23.9% vs. 4.9%, <i>P</i>=0.0001). Direct bilirubin (<i>P</i>=0.03) and albumin (<i>P</i>=0.04) levels significantly differed between the PTE and non-PTE groups. Notably, there was a significant difference in the partial thromboplastin time (<i>P</i>=0.04) between the PTE and non-PTE groups. A regression analysis indicated that age (OR, 1.02; 95% CI, 1.00‒1.004; <i>P</i>=0.005), blood pressure (OR, 2.07; 95% CI, 1.12‒3.85; <i>P</i>=0.02), heart attack (OR, 1.02; 95% CI, 1.28‒6.06; <i>P</i>=0.009), and albumin level (OR, 0.39; 95% CI, 0.16‒0.97; <i>P</i>=0.04) were all independent predictors of PTE development.</p><p><strong>Conclusion: </strong>Regression analysis revealed that age, blood pressure, heart attack, and albumin levels were independent predictors of PTE.</p>","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/14/f4/br-58-3-127.PMC10548293.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9823324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MicroRNA-765 is upregulated in myelodysplastic syndromes and induces apoptosis via PLP2 inhibition in leukemia cells. MicroRNA-765在骨髓增生异常综合征中上调,并通过抑制白血病细胞中的PLP2诱导细胞凋亡。
IF 2.2 Q3 Medicine Pub Date : 2023-09-30 Epub Date: 2023-07-27 DOI: 10.5045/br.2023.2023097
Seong-Ho Kang, Ji Seon Choi

Background: Epigenetic studies, particularly research on microRNA (miRNA), have flourished. The abnormal expression of miRNA contributes to the development of hematologic malignancies. miR-765 has been reported to inhibit cell proliferation by downregulating proteolipid protein 2 (PLP2), which causes apoptosis. We investigated miR-765 dysregulation in myelodysplastic syndromes (MDS).

Methods: We compared the expression profiles of miR-765 in 65 patients with MDS and 11 controls. Cell proliferation and apoptosis assays were performed to determine the in vitro effects of miR-765 on leukemia cells transfected with the miR-765 mimic. Reverse transcription quantitative PCR (RT-qPCR) and western blotting were performed to examine the targets of miR-765.

Results: We found that miR-765 levels were upregulated 10.2-fold in patients with MDS compared to controls. In refractory cytopenia with multilineage dysplasia, the percentage of patients with elevated miR-765 levels was significantly higher than in other forms of MDS. Experiments with leukemia cells revealed that transfection with a miR-765 mimic inhibited cell proliferation and induced apoptosis. RT-qPCR and western blotting demonstrated that the target of miR-765 was PLP2.

Conclusion: These findings imply that upregulation of miR-765 induces apoptosis via downregulation of PLP2 and may have a role in MDS pathogenesis.

背景:表观遗传学研究,特别是对微小RNA(miRNA)的研究已经蓬勃发展。miRNA的异常表达导致血液系统恶性肿瘤的发展。据报道,miR-765通过下调导致细胞凋亡的蛋白脂质蛋白2(PLP2)来抑制细胞增殖。我们研究了骨髓增生异常综合征(MDS)中miR-765的失调。方法:我们比较了65例MDS患者和11例对照组的miR-765表达谱。进行细胞增殖和凋亡测定以确定miR-765对用miR-765模拟物转染的白血病细胞的体外作用。进行逆转录定量PCR(RT-qPCR)和蛋白质印迹来检测miR-765的靶点。结果:我们发现,与对照组相比,MDS患者的miR-765水平上调了10.2倍。在多谱系发育不良的难治性细胞减少症中,miR-765水平升高的患者比例显著高于其他形式的MDS。对白血病细胞的实验显示,用miR-765模拟物转染抑制细胞增殖并诱导细胞凋亡。RT-qPCR和western印迹显示miR-765的靶点是PLP2。结论:这些发现表明miR-765上调通过下调PLP2诱导细胞凋亡,并可能在MDS的发病机制中发挥作用。
{"title":"MicroRNA-765 is upregulated in myelodysplastic syndromes and induces apoptosis via PLP2 inhibition in leukemia cells.","authors":"Seong-Ho Kang,&nbsp;Ji Seon Choi","doi":"10.5045/br.2023.2023097","DOIUrl":"10.5045/br.2023.2023097","url":null,"abstract":"<p><strong>Background: </strong>Epigenetic studies, particularly research on microRNA (miRNA), have flourished. The abnormal expression of miRNA contributes to the development of hematologic malignancies. miR-765 has been reported to inhibit cell proliferation by downregulating proteolipid protein 2 (PLP2), which causes apoptosis. We investigated miR-765 dysregulation in myelodysplastic syndromes (MDS).</p><p><strong>Methods: </strong>We compared the expression profiles of miR-765 in 65 patients with MDS and 11 controls. Cell proliferation and apoptosis assays were performed to determine the <i>in vitro</i> effects of miR-765 on leukemia cells transfected with the miR-765 mimic. Reverse transcription quantitative PCR (RT-qPCR) and western blotting were performed to examine the targets of miR-765.</p><p><strong>Results: </strong>We found that miR-765 levels were upregulated 10.2-fold in patients with MDS compared to controls. In refractory cytopenia with multilineage dysplasia, the percentage of patients with elevated miR-765 levels was significantly higher than in other forms of MDS. Experiments with leukemia cells revealed that transfection with a miR-765 mimic inhibited cell proliferation and induced apoptosis. RT-qPCR and western blotting demonstrated that the target of miR-765 was PLP2.</p><p><strong>Conclusion: </strong>These findings imply that upregulation of miR-765 induces apoptosis via downregulation of PLP2 and may have a role in MDS pathogenesis.</p>","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e7/7a/br-58-3-133.PMC10548289.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9930594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Concomitant ruxolitinib with cytarabine-based induction chemotherapy in secondary acute myeloid leukemia evolving from myeloproliferative neoplasm. 鲁索利替尼联合阿糖胞苷诱导化疗治疗由骨髓增生性肿瘤演变而来的继发性急性髓系白血病。
IF 2.2 Q3 Medicine Pub Date : 2023-09-30 Epub Date: 2023-08-25 DOI: 10.5045/br.2023.2023136
Dong Hyun Kim, Ja Min Byun, Dong-Yeop Shin, Inho Kim, Sung-Soo Yoon, Youngil Koh
Age 62 74 Gender F M MPN type Essential thrombocythemia Polycythemia vera AML diagnosis Feb 2019 Mar 2019 JAK2 status Negative Positive Other molecular status Complex karyotype, TP53, ROS1, FGFR4 mutations Not assessed Treatment 5+2 induction chemotherapy with ruxolitinib 5+2 induction chemotherapy with ruxolitinib Response to induction Complete remission Partial remission Response to consolidation Not assessed (EOT) Not assessed (EOT) EOT reason Septic pneumonia Deteriorated condition Duration of response 3 months + 24 months + OS 3 months 24 months + Outcome Deceased Medically stable after EOT
{"title":"Concomitant ruxolitinib with cytarabine-based induction chemotherapy in secondary acute myeloid leukemia evolving from myeloproliferative neoplasm.","authors":"Dong Hyun Kim,&nbsp;Ja Min Byun,&nbsp;Dong-Yeop Shin,&nbsp;Inho Kim,&nbsp;Sung-Soo Yoon,&nbsp;Youngil Koh","doi":"10.5045/br.2023.2023136","DOIUrl":"10.5045/br.2023.2023136","url":null,"abstract":"Age 62 74 Gender F M MPN type Essential thrombocythemia Polycythemia vera AML diagnosis Feb 2019 Mar 2019 JAK2 status Negative Positive Other molecular status Complex karyotype, TP53, ROS1, FGFR4 mutations Not assessed Treatment 5+2 induction chemotherapy with ruxolitinib 5+2 induction chemotherapy with ruxolitinib Response to induction Complete remission Partial remission Response to consolidation Not assessed (EOT) Not assessed (EOT) EOT reason Septic pneumonia Deteriorated condition Duration of response 3 months + 24 months + OS 3 months 24 months + Outcome Deceased Medically stable after EOT","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ff/9b/br-58-3-155.PMC10548284.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10423129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Persistent polyclonal B-cell lymphocytosis with buttock-like cells mimicking follicular lymphoma. 持续性多克隆B细胞淋巴细胞增多症伴类似滤泡性淋巴瘤的臀部样细胞。
IF 2.2 Q3 Medicine Pub Date : 2023-09-30 Epub Date: 2023-07-24 DOI: 10.5045/br.2023.2023116
Fnu Aakash, Sa A Wang, Karan Saluja, Beenu Thakral
A 52-year-old woman was found to have leukocytosis [19.4×10 9 /L (range, 4 – 11)] with absolute lymphocytosis [5.8×10 9 /L (range, 1 – 4.8)] for ∼ 1 year. Peripheral blood (PB) showed circulating atypical, binucleated and clefted lymphocytes mimicking “buttock cells” of follicular lymphoma. PB flow cytometry (FC) showed polytypic B-cell lymphocytosis (64.4%) expressing CD19 + CD20 + CD27 + IgM + and CD5 - CD10 - CD38 - . No cutaneous lesions were noted. A staging bone marrow showed no evidence of lymphoma. Cytogenetics showed a normal female karyotype. Serum IgM levels were increased [8.4 g/L (range, 0.35 – 2.4)], with normal IgA and IgG levels. Serum protein electrophoresis and immunofixation studies showed no M-protein. PET-CT showed no lymphadenopathy or hepatosplenomegaly. She had 30-years smoking history. Based on the above findings, persistent polyclonal B ‐ cell lymphocytosis (PPBL) was diagnosed. PPBL is a benign proliferation of memory B-cells in adult women with longstanding smoking history. Exact pathogenesis of PPBL is not known, potential mechanisms include defect in CD40 activation pathway or expansion of functional CD27 + memory B-cells. About 90% of PPBL cases are HLA-DR7-positive
{"title":"Persistent polyclonal B-cell lymphocytosis with buttock-like cells mimicking follicular lymphoma.","authors":"Fnu Aakash,&nbsp;Sa A Wang,&nbsp;Karan Saluja,&nbsp;Beenu Thakral","doi":"10.5045/br.2023.2023116","DOIUrl":"10.5045/br.2023.2023116","url":null,"abstract":"A 52-year-old woman was found to have leukocytosis [19.4×10 9 /L (range, 4 – 11)] with absolute lymphocytosis [5.8×10 9 /L (range, 1 – 4.8)] for ∼ 1 year. Peripheral blood (PB) showed circulating atypical, binucleated and clefted lymphocytes mimicking “buttock cells” of follicular lymphoma. PB flow cytometry (FC) showed polytypic B-cell lymphocytosis (64.4%) expressing CD19 + CD20 + CD27 + IgM + and CD5 - CD10 - CD38 - . No cutaneous lesions were noted. A staging bone marrow showed no evidence of lymphoma. Cytogenetics showed a normal female karyotype. Serum IgM levels were increased [8.4 g/L (range, 0.35 – 2.4)], with normal IgA and IgG levels. Serum protein electrophoresis and immunofixation studies showed no M-protein. PET-CT showed no lymphadenopathy or hepatosplenomegaly. She had 30-years smoking history. Based on the above findings, persistent polyclonal B ‐ cell lymphocytosis (PPBL) was diagnosed. PPBL is a benign proliferation of memory B-cells in adult women with longstanding smoking history. Exact pathogenesis of PPBL is not known, potential mechanisms include defect in CD40 activation pathway or expansion of functional CD27 + memory B-cells. About 90% of PPBL cases are HLA-DR7-positive","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/14/8a/br-58-3-125.PMC10548282.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9912193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hairy cell leukemia presenting as a pleural mass without leukemic component: a case report. 毛细胞白血病表现为胸膜肿块,无白血病成分:一例报告。
IF 2.2 Q3 Medicine Pub Date : 2023-09-30 Epub Date: 2023-08-25 DOI: 10.5045/br.2023.2023114
Ahmad Alshomrani, Jeffrey J Cannatella, Hina Qureishi
that analysis of 16S ribosomal RNA from the gut microbiome can be used to elucidate its effect on patient outcomes after transplantation [15]. Future studies should focus on the molecular mechanisms using metabolomic analyses. In summary, FMT shows promise for restoring microbial diversity and treating aGVHD in patients undergoing allo-HSCT. However, FMT remains experimental and the most effective route of administration, product formulation, volume, and frequency of the procedure has not yet been established. Further studies are required to evaluate the potential benefits of FMT in patients with steroid-refractory acute GVHD.
{"title":"Hairy cell leukemia presenting as a pleural mass without leukemic component: a case report.","authors":"Ahmad Alshomrani,&nbsp;Jeffrey J Cannatella,&nbsp;Hina Qureishi","doi":"10.5045/br.2023.2023114","DOIUrl":"10.5045/br.2023.2023114","url":null,"abstract":"that analysis of 16S ribosomal RNA from the gut microbiome can be used to elucidate its effect on patient outcomes after transplantation [15]. Future studies should focus on the molecular mechanisms using metabolomic analyses. In summary, FMT shows promise for restoring microbial diversity and treating aGVHD in patients undergoing allo-HSCT. However, FMT remains experimental and the most effective route of administration, product formulation, volume, and frequency of the procedure has not yet been established. Further studies are required to evaluate the potential benefits of FMT in patients with steroid-refractory acute GVHD.","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4d/77/br-58-3-148.PMC10548290.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10423127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ABO blood group and rhesus factor association with inpatient COVID-19 mortality and severity: a two-year retrospective review. ABO血型和恒河猴因子与住院新冠肺炎死亡率和严重程度的相关性:一项为期两年的回顾性审查。
IF 2.2 Q3 Medicine Pub Date : 2023-09-30 DOI: 10.5045/br.2023.2023122
Alexander T Phan, Ari A Ucar, Aldin Malkoc, Janie Hu, Luke Buxton, Alan W Tseng, Fanglong Dong, Julie P T Nguyễn, Arnav P Modi, Ojas Deshpande, Johnson Lay, Andrew Ku, Dotun Ogunyemi, Sarkis Arabian

Background: Early reports have indicated a relationship between ABO and rhesus blood group types and infection with SARS-CoV-2. We aim to examine blood group type associations with COVID-19 mortality and disease severity.

Methods: This is a retrospective chart review of patients ages 18 years or older admitted to the hospital with COVID-19 between January 2020 and December 2021. The primary outcome was COVID-19 mortality with respect to ABO blood group type. The secondary outcomes were 1. Severity of COVID-19 with respect to ABO blood group type, and 2. Rhesus factor association with COVID-19 mortality and disease severity. Disease severity was defined by degree of supplemental oxygen requirements (ambient air, low-flow, high-flow, non-invasive mechanical ventilation, and invasive mechanical ventilation).

Results: The blood type was collected on 596 patients with more than half (54%, N=322) being O+. The ABO blood type alone was not statistically associated with mortality (P=0.405), while the RH blood type was statistically associated with mortality (P<0.001). There was statistically significant association between combined ABO and RH blood type and mortality (P=0.014). Out of the mortality group, the O+ group had the highest mortality (52.3%), followed by A+ (22.8%). The combined ABO and RH blood type was statistically significantly associated with degree of supplemental oxygen requirements (P=0.005). The Kaplan-Meier curve demonstrated that Rh- patients had increased mortality.

Conclusion: ABO blood type is not associated with COVID-19 severity and mortality. Rhesus factor status is associated with COVID-19 severity and mortality. Rhesus negative patients were associated with increased mortality risk.

背景:早期报告表明ABO血型和恒河猴血型与严重急性呼吸系统综合征冠状病毒2型感染之间存在关系。我们的目的是检查血型与新冠肺炎死亡率和疾病严重程度的关系。方法:这是对2020年1月至2021年12月期间因新冠肺炎入院的18岁或18岁以上患者的回顾性图表回顾。主要结果是新冠肺炎ABO血型死亡率。次要结果为1。新冠肺炎与ABO血型相关的严重程度,以及2。恒河猴因子与新冠肺炎死亡率和疾病严重程度的关系。疾病的严重程度由补充氧气的程度(环境空气、低流量、高流量、无创机械通气和有创机械通气)来定义。结果:收集了596名患者的血型,其中超过一半(54%,N=322)为O+。仅ABO血型与死亡率无统计学相关性(P=0.405),而RH血型与死亡率有统计学相关性(PP=0.014)。在死亡率组中,O+组的死亡率最高(52.3%),其次是A+(22.8%)。ABO和RH的联合血型与补充氧气的程度有统计学意义(P=0.005)。Kaplan-Meier曲线表明RH患者的死亡率增加。结论:ABO血型与新冠肺炎的严重程度和死亡率无关。恒河猴因子状态与新冠肺炎的严重程度和死亡率相关。恒河猴阴性患者的死亡率增加。
{"title":"ABO blood group and rhesus factor association with inpatient COVID-19 mortality and severity: a two-year retrospective review.","authors":"Alexander T Phan,&nbsp;Ari A Ucar,&nbsp;Aldin Malkoc,&nbsp;Janie Hu,&nbsp;Luke Buxton,&nbsp;Alan W Tseng,&nbsp;Fanglong Dong,&nbsp;Julie P T Nguyễn,&nbsp;Arnav P Modi,&nbsp;Ojas Deshpande,&nbsp;Johnson Lay,&nbsp;Andrew Ku,&nbsp;Dotun Ogunyemi,&nbsp;Sarkis Arabian","doi":"10.5045/br.2023.2023122","DOIUrl":"https://doi.org/10.5045/br.2023.2023122","url":null,"abstract":"<p><strong>Background: </strong>Early reports have indicated a relationship between ABO and rhesus blood group types and infection with SARS-CoV-2. We aim to examine blood group type associations with COVID-19 mortality and disease severity.</p><p><strong>Methods: </strong>This is a retrospective chart review of patients ages 18 years or older admitted to the hospital with COVID-19 between January 2020 and December 2021. The primary outcome was COVID-19 mortality with respect to ABO blood group type. The secondary outcomes were 1. Severity of COVID-19 with respect to ABO blood group type, and 2. Rhesus factor association with COVID-19 mortality and disease severity. Disease severity was defined by degree of supplemental oxygen requirements (ambient air, low-flow, high-flow, non-invasive mechanical ventilation, and invasive mechanical ventilation).</p><p><strong>Results: </strong>The blood type was collected on 596 patients with more than half (54%, N=322) being O+. The ABO blood type alone was not statistically associated with mortality (P=0.405), while the RH blood type was statistically associated with mortality (<i>P</i><0.001). There was statistically significant association between combined ABO and RH blood type and mortality (<i>P</i>=0.014). Out of the mortality group, the O+ group had the highest mortality (52.3%), followed by A+ (22.8%). The combined ABO and RH blood type was statistically significantly associated with degree of supplemental oxygen requirements (<i>P</i>=0.005). The Kaplan-Meier curve demonstrated that Rh- patients had increased mortality.</p><p><strong>Conclusion: </strong>ABO blood type is not associated with COVID-19 severity and mortality. Rhesus factor status is associated with COVID-19 severity and mortality. Rhesus negative patients were associated with increased mortality risk.</p>","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fc/2b/br-58-3-138.PMC10548287.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41170202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Atypical posterior reversible encephalopathy syndrome secondary to dasatinib. 达沙替尼继发的非典型后部可逆性脑病综合征。
IF 2.2 Q3 Medicine Pub Date : 2023-09-30 DOI: 10.5045/br.2023.2023057
Amiya Ranjan Nayak, Deepika Yadav, Priyanka Naranje, Jasmita Dass, Pradeep Kumar, Mukul Aggarwal
with skin involvement (proven by skin biopsy) has been reported twice. Other differential diagnoses of HSTCL include aggressive natural killer cell leukemia (typically negative for surface CD3 on flow cytometry) and T-lymphoblastic leukemia [dim expression of CD45 and surface CD3 with expression of immaturity markers (TdT/CD34/CD1a)] [4, 6, 8]. The disease has an aggressive course, and most cases will relapse. Moreover, there is no known optimal therapy [1, 2, 7]. With conventional chemotherapy, complete remission is uncommon, and most patients die within two years of diagnosis [5, 9]. Long-term remission can be achieved by allogeneic stem cell transplantation, and studies have suggested that both autologous and allogeneic transplants may confer a potential cure for the disease with an estimated 3 years overall survival after allogeneic transplantation of 56% [2, 8]. One major limitation regarding staging and assessing the extent of lymphoma is the unavailability of bone and PET scans for the patient at diagnosis, which makes assessment of response for chemotherapy and evaluation for achievement of remission challenging.
{"title":"Atypical posterior reversible encephalopathy syndrome secondary to dasatinib.","authors":"Amiya Ranjan Nayak,&nbsp;Deepika Yadav,&nbsp;Priyanka Naranje,&nbsp;Jasmita Dass,&nbsp;Pradeep Kumar,&nbsp;Mukul Aggarwal","doi":"10.5045/br.2023.2023057","DOIUrl":"https://doi.org/10.5045/br.2023.2023057","url":null,"abstract":"with skin involvement (proven by skin biopsy) has been reported twice. Other differential diagnoses of HSTCL include aggressive natural killer cell leukemia (typically negative for surface CD3 on flow cytometry) and T-lymphoblastic leukemia [dim expression of CD45 and surface CD3 with expression of immaturity markers (TdT/CD34/CD1a)] [4, 6, 8]. The disease has an aggressive course, and most cases will relapse. Moreover, there is no known optimal therapy [1, 2, 7]. With conventional chemotherapy, complete remission is uncommon, and most patients die within two years of diagnosis [5, 9]. Long-term remission can be achieved by allogeneic stem cell transplantation, and studies have suggested that both autologous and allogeneic transplants may confer a potential cure for the disease with an estimated 3 years overall survival after allogeneic transplantation of 56% [2, 8]. One major limitation regarding staging and assessing the extent of lymphoma is the unavailability of bone and PET scans for the patient at diagnosis, which makes assessment of response for chemotherapy and evaluation for achievement of remission challenging.","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/90/66/br-58-3-161.PMC10548285.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41152099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Venetoclax-azacitidine as salvage therapy for relapsed mixed phenotype acute leukemia after a second allogeneic hematopoietic stem cell transplantation: a case report. 第二次异基因造血干细胞移植后复发的混合表型急性白血病的补救性治疗:1例报告。
IF 2.2 Q3 Medicine Pub Date : 2023-06-30 DOI: 10.5045/br.2023.2023061
Sabrine Mekni, Rimmel Yosra Kanoun, Saloua Ladeb, Dorra Belloumi, Nour Ben Abdeljelil, Tarek Ben Othman
TO THE EDITOR: Mixed phenotype acute leukemia (MPAL) is rare, accounting for approximately 1–4% of acute leukemia (AL) cases [1]. Induction therapy for these cases is often based on acute lymphocytic leukemia (ALL) treatment protocols, followed by allogeneic stem cell transplantation (ASCT). However, post-ASCT relapse after ASCT remains the primary cause of treatment failure. The median overall survival (OS) of patients who relapse after ASCT is extremely poor, with a median 3-year survival rate ranging between 9% and 11% [2]. Recent studies have reported better survival rates with a combination of venetoclax (VEN) and hypomethylating agents (HMA). Here, we describe the case of a 36-year-old patient with B/T MPAL who developed medullary relapse after 2 ASCTs and was successfully treated with VEN and azacitidine (VEN-AZA).
{"title":"Venetoclax-azacitidine as salvage therapy for relapsed mixed phenotype acute leukemia after a second allogeneic hematopoietic stem cell transplantation: a case report.","authors":"Sabrine Mekni,&nbsp;Rimmel Yosra Kanoun,&nbsp;Saloua Ladeb,&nbsp;Dorra Belloumi,&nbsp;Nour Ben Abdeljelil,&nbsp;Tarek Ben Othman","doi":"10.5045/br.2023.2023061","DOIUrl":"https://doi.org/10.5045/br.2023.2023061","url":null,"abstract":"TO THE EDITOR: Mixed phenotype acute leukemia (MPAL) is rare, accounting for approximately 1–4% of acute leukemia (AL) cases [1]. Induction therapy for these cases is often based on acute lymphocytic leukemia (ALL) treatment protocols, followed by allogeneic stem cell transplantation (ASCT). However, post-ASCT relapse after ASCT remains the primary cause of treatment failure. The median overall survival (OS) of patients who relapse after ASCT is extremely poor, with a median 3-year survival rate ranging between 9% and 11% [2]. Recent studies have reported better survival rates with a combination of venetoclax (VEN) and hypomethylating agents (HMA). Here, we describe the case of a 36-year-old patient with B/T MPAL who developed medullary relapse after 2 ASCTs and was successfully treated with VEN and azacitidine (VEN-AZA).","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/28/08/br-58-2-118.PMC10310488.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10111922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A survey evaluating hematology physicians’ perspectives on central nervous system prophylaxis. 血液学医生对中枢神经系统预防的看法。
IF 2.2 Q3 Medicine Pub Date : 2023-06-30 DOI: 10.5045/br.2023.2023066
Ufuk Demirci, Meltem Kurt Yüksel, Hakki Onur Kırkızlar, Elif Birtaş Ateşoğlu, Özgür Mehtap, Ozan Salim, Ahmet Muzaffer Demir, Olga Meltem Akay

Background: Central nervous system (CNS) prophylactic options for diffuse large B-cell lymphoma (DLBCL) are administered differently in most centers. Unfortunately, there is still not a consensus on which patients, which regimen, for how many cycles, and when prophylaxis should be administered. Thus, this remains an unmet clinical need.

Methods: We administered a survey study under the Lymphoma Scientific Subcommittee of the Turkish Society of Haematology. The questions were directed to hematologists through the monkey survey system.

Results: The CNS International Prognostic Index score is a factor that clinicians frequently use when deciding on prophylaxis and is considered reliable. Although the perspective on anatomical risk factors is similar to that reported in the literature, breast involvement is still considered a critical risk factor in Turkey. Participants considered double or triple hit and double/triple expressor lymphoma as significant risk factors. Various methods have been used to demonstrate CNS relapses. Intrathecal prophylaxis is the preferred method.

Conclusion: There are diverse methodological and technical ideas. The controversial results reported in the literature on the effectiveness of CNS prophylaxis may explain this finding. Although CNS prophylactic methods for patients with DLBCL are still controversial, the effect of secondary CNS involvement on survival is inevitable. Standard practices followed by national guidelines may be effective in reducing the variety of application methods and creating homogeneous results for efficacy and survival follow-up studies.

背景:在大多数中心,弥漫性大b细胞淋巴瘤(DLBCL)的中枢神经系统(CNS)预防方案是不同的。不幸的是,对于哪些患者,哪种治疗方案,需要多少周期,以及何时应该进行预防,仍然没有达成共识。因此,这仍然是一个未满足的临床需求。方法:我们在土耳其血液病学会淋巴瘤科学小组委员会下进行了一项调查研究。这些问题是通过猴子调查系统直接向血液学家提出的。结果:CNS国际预后指数评分是临床医生在决定预防措施时经常使用的一个因素,被认为是可靠的。尽管解剖危险因素的观点与文献报道相似,但在土耳其,乳房受累仍被认为是一个关键的危险因素。参与者认为双重或三重打击和双重/三重表达淋巴瘤是重要的危险因素。各种方法被用来证明中枢神经系统的复发。鞘内预防是首选方法。结论:有不同的方法和技术思路。文献中关于中枢神经系统预防有效性的有争议的结果可能解释了这一发现。尽管DLBCL患者的中枢神经系统预防方法仍存在争议,但继发性中枢神经系统受损伤对生存的影响是不可避免的。国家指南遵循的标准做法可能有效地减少应用方法的多样性,并为疗效和生存随访研究创造一致的结果。
{"title":"A survey evaluating hematology physicians’ perspectives on central nervous system prophylaxis.","authors":"Ufuk Demirci,&nbsp;Meltem Kurt Yüksel,&nbsp;Hakki Onur Kırkızlar,&nbsp;Elif Birtaş Ateşoğlu,&nbsp;Özgür Mehtap,&nbsp;Ozan Salim,&nbsp;Ahmet Muzaffer Demir,&nbsp;Olga Meltem Akay","doi":"10.5045/br.2023.2023066","DOIUrl":"https://doi.org/10.5045/br.2023.2023066","url":null,"abstract":"<p><strong>Background: </strong>Central nervous system (CNS) prophylactic options for diffuse large B-cell lymphoma (DLBCL) are administered differently in most centers. Unfortunately, there is still not a consensus on which patients, which regimen, for how many cycles, and when prophylaxis should be administered. Thus, this remains an unmet clinical need.</p><p><strong>Methods: </strong>We administered a survey study under the Lymphoma Scientific Subcommittee of the Turkish Society of Haematology. The questions were directed to hematologists through the monkey survey system.</p><p><strong>Results: </strong>The CNS International Prognostic Index score is a factor that clinicians frequently use when deciding on prophylaxis and is considered reliable. Although the perspective on anatomical risk factors is similar to that reported in the literature, breast involvement is still considered a critical risk factor in Turkey. Participants considered double or triple hit and double/triple expressor lymphoma as significant risk factors. Various methods have been used to demonstrate CNS relapses. Intrathecal prophylaxis is the preferred method.</p><p><strong>Conclusion: </strong>There are diverse methodological and technical ideas. The controversial results reported in the literature on the effectiveness of CNS prophylaxis may explain this finding. Although CNS prophylactic methods for patients with DLBCL are still controversial, the effect of secondary CNS involvement on survival is inevitable. Standard practices followed by national guidelines may be effective in reducing the variety of application methods and creating homogeneous results for efficacy and survival follow-up studies.</p>","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/99/6a/br-58-2-99.PMC10310485.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9738278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Blood Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1